Work

Iron Chelators for Thalassaemia

Year: 1998
Type: review
Abstract: IRON CHELATORS FOR THALASSAEMIAThe iron-chelating compound desferrioxamine (DFO) was discovered accidentally, as a byproduct of antibiotic research by scientists in the Swiss Federal Institute of Technology in Zurich and Ciba in Basel.Its development into a useful clinical drug was not by design, but thanks to natural curiosity and ingenuity, as described by Keberle (1992).Although DFO has been available for treating transfusional iron overload from the early 1960s, the era of modern and effective iron-chelating therapy started only 20 years ago with the introduction of subcutaneous DFO infusions by portable pumps.Today, long-term DFO therapy is an integral part of the management of thalassaemia and other transfusion-dependent anaemias, with a major impact on wellbeing and survival.In this Review we will discuss the abnormalities in iron metabolism associated with thalassaemia major and the chelatable iron pools representing the targets of iron-chelating therapy, examine the results of longterm DFO therapy in thalassaemia, and, finally, review the development of new, orally effective, iron chelators which may be considered for present or future use.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2146033714
FWCI: 3.23
Cites: 67
Cited by: 158
Related to: 10